Penulis: John Morrow

Zoran Rankovic is a Senior Research Fellow and a Head of Medicinal Chemistry section at MSD, Merck Research Laboratories, U.K. 15 years experience in drug discovery with a track record of delivering compounds into the development for a number of therapeutic areas, including psychiatry. Over a decade of a direct involvement in shaping the early discovery portfolio for the neuroscience franchise. Zoran has a Ph D in organic chemistry from the University of Leeds, UK. Richard Hargreaves is Vice President and Worldwide Head of Neuroscience Discovery Research at Merck – completed his doctorate through the Physiology Department at King”s College London University UK. Joined Merck”s Neuroscience Research Center in Harlow UK in 1988. Leader of the discovery biology teams that contributed to the development of MAXALT(R) (rizatriptan) for the treatment of migraine and EMEND(R) (aprepitant) and IVEMEND(R) (fosaprepitant), novel agents that advance the protective pharmacotherapy of acute and delayed chemotherapy-induced nausea and vomiting and post-operative nausea and vomiting. In 1999 he became Vice President Worldwide Head of Imaging with the assignment to establish and lead a worldwide imaging research strategy for Merck Research Laboratories. Matilda Bingham is currently Team Leader in the Medicinal Chemistry Department, MSD; 8 years research experience in neuroscience research in a pharmaceutical setting, participating and leading teams in the neuroscience area, specialising in the transporter and GPCR target classes.